Search results
Results from the WOW.Com Content Network
Structures with names 4- and 5-nitroimidazole are equivalent from the perspective of drugs since these tautomers readily interconvert. Drugs of the 5-nitro variety include metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, ornidazole, megazol, and azanidazole. Drugs based on 2-nitroimidazoles include benznidazole and azomycin. [3]
[9] [10] These drugs had been further developed prior to the COVID-19 pandemic for other diseases including SARS. [11] The utility of targeting the 3CL protease in a real world setting was first demonstrated in 2018 when GC376 (a prodrug of GC373) was used to treat the previously 100% lethal cat coronavirus disease, feline infectious ...
The 5-nitroimidazole drugs (metronidazole and tinidazole) are the mainstay of treatment for infection with Trichomonas vaginalis. Treatment for both the infected patient and the patient's sexual partner is recommended, even if asymptomatic. Therapy other than 5-nitroimidazole drugs is also an option, but cure rates are much lower. [26]
In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir can reduce the risk of hospitalization or death by 88% if taken within five days of symptom onset. [20] People who take nirmatrelvir/ritonavir also test negative for COVID‑19 about two and a half days earlier than people who do not. [21]
[5] [93] [94] [95] One study from April 2020 found that people with COVID-19 and hypertension had lower all-cause mortality when on these medications. [96] Similar concerns were raised about non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen; these were likewise not borne out, and NSAIDs may both be used to relieve symptoms of ...
Benznidazole is a nitroimidazole antiparasitic with good activity against acute infection with Trypanosoma cruzi, commonly referred to as Chagas disease. [14] Like other nitroimidazoles, benznidazole's main mechanism of action is to generate radical species which can damage the parasite's DNA or cellular machinery. [17]
CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.
It is in the nitroimidazole class of medications. [5] Delamanid was approved for medical use in 2014 in Europe, Japan, and South Korea. [6] It is on the World Health Organization's List of Essential Medicines. [7] As of 2016 the Stop TB Partnership had an agreement to get the medication for US$1,700 per six month for use in more than 100 ...